Somewhat Favorable News Coverage Somewhat Unlikely to Impact Stryker (SYK) Share Price
Headlines about Stryker (NYSE:SYK) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 46.2540876881421 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Stryker Co. (SYK) Rating Reiterated by Argus (americanbankingnews.com)
- SunTrust Banks Comments on Stryker Corporation’s Q3 2017 Earnings (SYK) (americanbankingnews.com)
- Q3 2017 Earnings Estimate for Stryker Corporation Issued By Northcoast Research (SYK) (americanbankingnews.com)
- Stryker Corporation’s (SYK) Overweight Rating Reaffirmed at Piper Jaffray Companies (americanbankingnews.com)
- Stryker Corporation (SYK) Expected to Announce Quarterly Sales of $2.98 Billion (americanbankingnews.com)
Stryker (NYSE:SYK) opened at 139.41 on Wednesday. The stock has a 50 day moving average of $144.80 and a 200 day moving average of $137.03. The firm has a market capitalization of $52.15 billion, a PE ratio of 31.12 and a beta of 0.80. Stryker has a 12 month low of $106.48 and a 12 month high of $148.84.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker had a return on equity of 15.89% and a net margin of 12.98%. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same period in the prior year, the company posted $1.39 EPS. The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities analysts predict that Stryker will post $6.47 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a $0.425 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a yield of 1.22%. Stryker’s payout ratio is 37.95%.
SYK has been the subject of several research analyst reports. BMO Capital Markets reaffirmed a “hold” rating and set a $140.00 target price on shares of Stryker in a report on Tuesday, July 11th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Stryker in a report on Monday, June 19th. Citigroup Inc. lifted their target price on shares of Stryker from $114.00 to $125.00 and gave the stock a “sell” rating in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Stryker in a report on Thursday, June 29th. They set a “neutral” rating and a $153.00 target price for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $160.00 target price (up previously from $155.00) on shares of Stryker in a report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $145.73.
In other news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the transaction, the insider now directly owns 8,983 shares in the company, valued at approximately $1,313,853.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Floyd sold 19,305 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders sold a total of 32,810 shares of company stock valued at $4,754,958 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Stock Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related stocks with our FREE daily email newsletter.